Insider · CIK 0001217126
William M Moore
director
Files at IRIX (IRIDEX CORP). First filing Apr 23, 2025, latest Dec 18, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
8 / 0
$178k bought, $0 sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
IRIX: IRIDEX CORP
IRIXOct 9, 2026 · close 0.89
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 38Weak | IRIDEX CORP | $2,020 2,000 shares | +1% | +28% from low-45% from high | |
| 49Moderate | IRIDEX CORP | $48k 50,000 shares | +25% | +24% from low-48% from high | |
| 39Weak | IRIDEX CORP | $14k 12,024 shares | +6% | +48% from low-42% from high | |
| 46Moderate | IRIDEX CORP | $19k 20,000 shares | +12% | +19% from low-54% from high | |
| 54Moderate | IRIDEX CORP | $29k 30,000 shares | +22% | +18% from low-54% from high | |
| 39Weak | IRIDEX CORP | $19k 17,500 shares | +14% | +27% from low-51% from high | |
| 46Moderate | IRIDEX CORP | $24k 20,000 shares | +20% | +65% from low-36% from high | |
| 44Moderate | IRIDEX CORP | $21k 20,000 shares | +25% | +30% from low-49% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 16, 2025 | IRIX IRIDEX CORP | POpen-market purchase Common Stock | +2,000 | $1.01 | $2,020 | 251,550 | Dec 18, 2025 |
| Dec 15, 2025 | IRIX IRIDEX CORP | POpen-market purchase Common Stock | +20,000 | - | - | 249,550 | Dec 16, 2025 |
| Dec 11, 2025 | IRIX IRIDEX CORP | POpen-market purchase Common Stock | +9,080 | - | - | 259,754 | Dec 15, 2025 |
| Dec 12, 2025 | IRIX IRIDEX CORP | POpen-market purchase Common Stock | +20,920 | - | - | 280,674 | Dec 15, 2025 |
| Nov 14, 2025 | IRIX IRIDEX CORP | POpen-market purchase Common Stock | +28,157 | $0.97 | $27k | 228,831 | Nov 18, 2025 |
| Nov 17, 2025 | IRIX IRIDEX CORP | POpen-market purchase Common Stock | +21,843 | $0.97 | $21k | 250,674 | Nov 18, 2025 |
| Aug 18, 2025 | IRIX IRIDEX CORP | POpen-market purchase Common Stock | +12,024 | $1.18 | $14k | 200,674 | Aug 19, 2025 |
| Jun 13, 2025 | IRIX IRIDEX CORP | AGrant or award Common Stock (right to buy)derivative | +53,000 | $0.00 | $0 | 53,000 | Jun 24, 2025 |
| Jun 13, 2025 | IRIX IRIDEX CORP | AGrant or award Common Stock (right to buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Jun 24, 2025 |
| Jun 13, 2025 | IRIX IRIDEX CORP | POpen-market purchase Common Stock | +20,000 | $0.97 | $19k | 188,650 | Jun 16, 2025 |
| Jun 11, 2025 | IRIX IRIDEX CORP | POpen-market purchase Common Stock | +10,000 | $0.96 | $9,627 | 148,650 | Jun 13, 2025 |
| Jun 12, 2025 | IRIX IRIDEX CORP | POpen-market purchase Common Stock | +20,000 | $0.97 | $19k | 168,650 | Jun 13, 2025 |
| May 14, 2025 | IRIX IRIDEX CORP | POpen-market purchase Common Stock | +15,000 | $1.10 | $17k | 136,150 | May 16, 2025 |
| May 15, 2025 | IRIX IRIDEX CORP | POpen-market purchase Common Stock | +2,500 | $1.00 | $2,503 | 138,650 | May 16, 2025 |
| Apr 28, 2025 | IRIX IRIDEX CORP | POpen-market purchase Common Stock | +290 | $1.24 | $360 | 101,440 | Apr 30, 2025 |
| Apr 29, 2025 | IRIX IRIDEX CORP | POpen-market purchase Common Stock | +19,710 | $1.21 | $24k | 121,150 | Apr 30, 2025 |
| Apr 21, 2025 | IRIX IRIDEX CORP | POpen-market purchase Common Stock | +10,000 | $1.05 | $11k | 91,150 | Apr 23, 2025 |
| Apr 22, 2025 | IRIX IRIDEX CORP | POpen-market purchase Common Stock | +10,000 | $1.08 | $11k | 101,150 | Apr 23, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.